Research Keyword: psychedelic-assisted therapy

Down the rabbit hole – the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions

Psychedelic compounds like psilocybin and LSD are showing significant promise for treating various mental health conditions including depression, anxiety, and PTSD. These substances appear to work through multiple mechanisms, including inducing profound mystical experiences and increasing neuroplasticity in the brain. Research indicates that environmental and contextual factors significantly influence how effective these treatments are, and even virtual reality experiences mimicking psychedelic effects show therapeutic benefits. The field is moving toward responsible, evidence-based clinical applications of psychedelics in psychiatry.

Read More »

Virtual reality and psychedelics: new perspectives and new possibilities in the treatment of alcohol use disorder

This article discusses how virtual reality technology that simulates psychedelic experiences could improve treatment for alcohol addiction. Virtual reality simulations can mimic the brain effects of psychedelics like psilocybin, and could help prepare patients for treatment, extend its benefits, or even work as a standalone therapy. This innovation could make psychedelic-assisted therapy more accessible and easier to standardize across different treatment centers.

Read More »

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

This review examines how psychedelic substances like psilocybin and MDMA, when combined with professional psychotherapy, show promise in treating difficult-to-treat mental health conditions including depression, PTSD, and anxiety. While early research suggests these substances could help in cases where conventional treatments have failed, the evidence is still preliminary and limited by small study sizes. Psychedelics appear to work by changing how the brain processes information and memories, though much more rigorous research is needed before they can be considered standard treatments.

Read More »

Psychedelics and Suicide-Related Outcomes: A Systematic Review

This comprehensive review examined how psychedelic substances like psilocybin and MDMA affect suicidal thoughts. Overall, psilocybin and MDMA-assisted therapy showed promise in reducing suicidal ideation in controlled clinical settings, with effects appearing within weeks. However, LSD use was associated with increased suicidal thoughts. The researchers conclude that while psychedelics show potential, more research is needed to ensure safety and understand how they work.

Read More »

Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review

This research review examines how psilocybin, a compound from certain mushrooms, may help treat depression by creating changes in both brain function and psychological experience. Within supportive therapeutic settings, psilocybin appears to increase cognitive flexibility, help people better process emotions, and restore a sense of connection to themselves, others, and the world. The antidepressant benefits seem to work through a combination of direct brain changes and psychotherapeutic factors, rather than through pure pharmacological action alone.

Read More »

Psychedelic use in Poland: prevalence, correlates and social attitudes

This study found that about 6% of Polish adults have tried psychedelic drugs like LSD or magic mushrooms, mostly young men in cities driven by curiosity. Most users took these substances at home and described mixed experiences. While negative attitudes toward psychedelics were common overall, people with meditation experience and previous psychedelic use had more positive views about their therapeutic potential.

Read More »

Biological studies of clavine alkaloids targeting CNS receptors

This paper reviews clavine alkaloids, a class of natural compounds from ergot fungi that show promise as psychiatric medications. Unlike well-known psychedelics like LSD, clavine alkaloids may provide therapeutic benefits for anxiety and depression without strong hallucinogenic effects. The authors highlight how these compounds interact with brain receptors in ways that could make them safer and more effective medications for treating mood and neurological disorders.

Read More »

Postpartum depression: A role for psychedelics?

Postpartum depression affects many new mothers and involves feelings of disconnection from themselves and their babies. This review suggests that psilocybin, the active compound in psychedelic mushrooms, might help by promoting reconnection and acceptance. The authors examine safety data suggesting psilocybin could potentially be used safely in postpartum women if appropriate precautions are taken, such as temporarily stopping breastfeeding after treatment.

Read More »

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

This study explored how patients with severe depression that didn’t respond to typical treatments experienced psilocybin therapy. Researchers interviewed 11 patients about their experiences and found that building trust with therapists, managing expectations, and having multiple treatment sessions were crucial. Many patients found the experience intense and overwhelming, and most wanted ongoing support to understand what they experienced and how it affected their recovery.

Read More »
Scroll to Top